Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors.
Year: 2016
Type: article
Abstract: Alirocumab (Praluent): first in the new class of PCSK9 inhibitors.
Source: PubMed
Authors: Marina Manniello, Michele Pisano
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2413208148
